Bechstein, Matthias http://orcid.org/0000-0002-5652-7499
McDonough, Rosalie
Fiehler, Jens
Zanolini, Umberto
Rai, Hamid
Siddiqui, Adnan
Shotar, Eimad
Rouchaud, Aymeric
Goyal, Mayank
Gellissen, Susanne
Funding for this research was provided by:
Universitätsklinikum Hamburg-Eppendorf (UKE)
Article History
Received: 19 August 2021
Accepted: 5 January 2022
First Online: 14 February 2022
Conflict of interest
: J. Fiehler: Grants or contracts from any entity: Acandis, Cerenovus, Medtronic, Microvention, Stryker, all research funding, unrelated; Consulting fees: Acandis, Cerenovus, Medtronic, Microvention, Stryker, Penumbra, Phenox; Participation on a Data Safety Monitoring Board or Advisory Board: Stryker; Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid: ESMINT president (unpaid); Stock or stock options: Tegus Medical. A. Siddiqui: Financial interest/investor/stock options/ownership: Amnis Therapeutics, Apama Medical, Blink TBI Inc., Buffalo Technology Partners Inc., Cardinal Consultants, Cerebrotech Medical Systems, Inc., Cognition Medical, Endostream Medical Ltd, Imperative Care, International Medical Distribution Partners, Neurovascular Diagnostics Inc., Q’Apel Medical Inc, Rebound Therapeutics Corp., Rist Neurovascular Inc., Serenity Medical Inc., Silk Road Medical, StimMed, Synchron, Three Rivers Medical Inc., Viseon Spine Inc.; Consultant/Advisory Board: Amnis Therapeutics, Boston Scientific, Canon Medical Systems USA Inc., Cerebrotech Medical Systems Inc., Cerenovus, Corindus Inc., Endostream Medical Ltd, Guidepoint Global Consulting, Imperative Care, Integra LifeSciences Corp., Medtronic, MicroVention, Northwest University–DSMB Chair for HEAT Trial, Penumbra, Q’Apel Medical Inc., Rapid Medical, Rebound Therapeutics Corp., Serenity Medical Inc., Silk Road Medical, StimMed, Stryker, Three Rivers Medical, Inc., VasSol, W.L. Gore & Associates; Principal Investigator/steering comment of the following trials: Cerenovus NAPA and ARISE II; Medtronic SWIFT PRIME and SWIFT DIRECT; MicroVention FRED & CONFIDENCE; MUSC POSITIVE; and Penumbra 3D Separator, COMPASS, and INVEST. E. Shotar: Grants or contracts from any entity: Principal investigator of the EMPROTECT randomized controlled trial related to CSDH embolization The recipient of the PHRC-IR public grant funding the trial is AP-HP (Assistance Publique Hopitaux de Paris). M. Bechstein, R. McDonough, U. Zanolini, H. Rai, A. Rouchaud, M. Goyal and S. Gellissen declare that they have no competing interests.